摘要
组蛋白去乙酰化酶抑制剂(HDACi)是一类新的化疗药物,能够有效抑制组蛋白去乙酰化酶的活性,促进组蛋白及非组蛋白的乙酰化修饰,在转录和翻译后修饰水平调控肿瘤靶蛋白及凋亡相关蛋白的表达和降解,活化凋亡信号通路,诱导肿瘤细胞凋亡。本文以汤森路透(Thomson Reuters)的科学引文索引数据库扩展版(SCI-E)作为数据源,利用其开发的汤森数据分析器(TDA),基于数量和关键词从国家、机构和研究主题等方面,对截至2012年发表的组蛋白去乙酰化酶抑制剂相关研究论文进行了分析,从文献计量学角度揭示了该领域的国际发展趋势和特点。
Histone deacetylase inhibitor （HDACi） is a new generation of chemotherapeutic agents, which induce acetylation of histone proteins and non-histone proteins by inhibiting the activity of histone deacetylase. As acetylation of proteins facilitates the expression of proapoptotic genes and induces the degradation of oncoproteins and antiapoptotic proteins, HDACi induces apoptosis by activating the apoptotic signal transduction pathways at transcription and posttranslation levels. In this paper, the articles on HDACi from the database of Science Citation Index-Expanded published before 2012 （including 2012） were analyzed by the software of Thomson Data Analyzer（TDA）. The distribution of articles by time, country and institution, as well as the focus themes were indicated, influence of targeted countries and institutions were discussed, and the international status and trends of molecular HDACi were revealed.
出处
《生命科学仪器》
2013年第5期51-56,共6页
Life Science Instruments
